What is IDEXX Laboratories, Inc. (IDXX) DCF Fair Value and Intrinsic Value in 2026?

IDEXX Laboratories, Inc. (IDXX) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is IDEXX Laboratories, Inc.'s historical Return on Invested Capital (ROIC) and Moat Rating?

IDEXX Laboratories, Inc. operates in the Healthcare sector (Diagnostics & Research) with an economic moat rating of WIDE. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is IDEXX Laboratories, Inc.'s financial health rating and Piotroski F-Score?

IDEXX Laboratories, Inc.'s balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor IDEXX Laboratories, Inc. (IDXX) for quarterly SEC filing thesis breaks?

LocalAlpha audits IDEXX Laboratories, Inc.'s 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksIDXX

IDXX

IDEXX Laboratories, Inc.Healthcare / Diagnostics & ResearchINTACT

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Share Price

$503.90

52W: $500.61 - $769.98

DCF Fair Value

$349.93

-44% Premium

Thesis Hub

P/E (TTM)

35.4x

ROIC

26.3%

Operating Margin

35%

FCF Yield

2.3%

Debt / Equity

0.68x

Piotroski Score

6/9

Altman Z-Score

3.08

Market Cap

$39.7B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($349.93)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$349.93

MOS Buy Target (-25%)

$262.45

Valuation Overlays: DCF Fair Value ($349.93) 25% MOS Buy Target ($262.45) Revised Graham ($453.94) Graham Number ($80.91)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$503.90

DCF Fair Value

$348.93

-44.4% Premium

Starting Free Cash Flow ($M)$909M

$100M$909M (Reported)$50,000M

Stage 1 Growth (Years 1-5)17.5%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$900M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$11.6B

PV of Terminal Value

$16.9B

Implied Enterprise Value

$28.5B

Implied Equity Value

$27.6B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$1,068	$1,255	$1,475	$1,733	$2,036	$2,128	$2,223	$2,323	$2,428	$2,537
Present Value (PV)	$980	$1,056	$1,139	$1,227	$1,323	$1,269	$1,216	$1,166	$1,118	$1,072

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-522.7% Premium

$80.92

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $14.23BVPS: $20.45

Revised Graham Formula-11% Premium

$453.94

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings2.2% Yield

$10.93 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.9BYield: 2.2%

Reverse DCF: Market Growth Expectation

HIGH BARRIER

16.0% CAGR (Next 10 Yrs)

At the current price of $503.90, the market is assuming the business will compound Free Cash Flow at 16.0% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil IDXX with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for IDEXX Laboratories, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 35% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track IDXX & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: IDEXX Laboratories, Inc. (IDXX) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for IDEXX Laboratories, Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, IDEXX Laboratories, Inc. has an estimated DCF intrinsic fair value of $349.93 per share compared to its current market price of $503.90. This represents an estimated 44.0% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $80.91.